Giuseppe MichieliImmunogenicity, reactogenicity and #safety to assess #booster #vaccinations with #BNT162b2 or double-dose #mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) – final report, https://etidiohnew.blogspot.com/2026/02/immunogenicity-reactogenicity-and.html
Effectiveness of #BNT162b2 and #mRNA-1273 #JN1-adapted #vaccines against #COVID19-associated #hospitalisation and #death ..., https://etidiohnew.blogspot.com/2025/07/effectiveness-of-bnt162b2-and-mrna-1273.html
Early #effectiveness of #BNT162b2 #KP2 #vaccine against #COVID19 in #US VA #Healthcare System, https://etidiohnew.blogspot.com/2025/04/early-effectiveness-of-bnt162b2-kp2.html
#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines
Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…
#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines
Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more …
AuscandocPersistence of immune responses of a self-amplifying RNA #COVID19vaccine (ARCT-154) versus #BNT162b2 - The Lancet Infectious Diseases https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2824%2900060-4/fulltext “a booster dose of the novel #mRNAVaccine, #ARCT154, a self-amplifying mRNA (#saRNA) vaccine based on the #SARSCoV2 D614G variant (B.1), induced superior immunogenicity than BNT162b2 (Comirnaty; Pfizer–BioNTech) in BNT162b2-primed adults 1 month after administration.”
[Correspondence] Immune responses following #BNT162b2 #XBB15 #vaccination in patients on #haemodialysis in #Germany https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00783-1/fulltext?rss=yes
#Humoral and #cellular immune responses following #BNT162b2 #XBB15 #vaccination, Lancet Infect Dis.: https://doi.org/10.1016/S1473-3099(23)00690-4
#Cerebellar and brainstem #stroke possibly associated with #booster dose of #BNT162b2 (Pfizer-BioNTech) #COVID-19 #vaccine https://pubmed.ncbi.nlm.nih.gov/37147105/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1854v2hhZnt0mgKVJH6nZTbknw5s3TIKHPNU4VUvcT-3jqFIGc&fc=None&ff=20230508102045&v=2.17.9.post6+86293ac
Cerebellar and brainstem stroke possibly associated with booster dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine - PubMed
As COVID-19 vaccination becomes widely available and administered globally, there have been several reports of side effects attributed to the vaccine. This report highlights a patient who developed stroke 2 days following the administration of the COVID-19 vaccine, although its association remains u …
#Effectiveness of #BNT162b2 #Vaccine against #Omicron #Variant Infection among #Children 5–11 Years of Age, Israel https://wwwnc.cdc.gov/eid/article/29/4/22-1285_article
[Correspondence] #BNT162b2 #antigen dose and #SARS-CoV-2 #omicron infection in #adolescents https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00005-1/fulltext?rss=yes